Nationally Renowned Morton Plant Mease Surgeon Honored by Commission on Cancer|
Dr. Peter Blumencranz Receives Cancer Liaison Physician Outstanding Performance Award
CLEARWATER, Fla., (October 28, 2008) - For his exceptional leadership and dedication to cancer care, Peter W. Blumencranz, M.D., surgical oncologist and medical director of the Morton Plant Mease Comprehensive Breast Program has been awarded the 2008 Cancer Liaison Physician Outstanding Performance Award from the Commission on Cancer (CoC) of the American College of Surgeons.
“Dr. Blumencranz’s expertise and direction have been critical to putting the Morton Plant Mease Comprehensive Breast Program on the map and making it the nationally known leader in cancer care that it is today. He is to be commended for this extraordinary honor,” said Philip K. Beauchamp, F.A.C.H.E., president and chief executive officer, Morton Plant Mease Health Care.
In 2007, Dr. Blumencranz led the national clinical trial for GeneSearchTM - the first gene-based test to detect the spread of breast cancer into lymph nodes. Morton Plant Hospital in Clearwater became the first hospital in the United States to use GeneSearch which can determine in just minutes - while a patient is in surgery - if cancer has spread to the patient’s lymph nodes. If the cancer has spread, the lymph nodes can be removed immediately, avoiding the risk, stress and emotional trauma of a second surgery.
Recognition for the Cancer Liaison Physician Outstanding Performance Award will be given at the annual Cancer Liaison Physician breakfast to be held in San Francisco in October. Dr. Blumencranz is one of only 55 physicians nationwide to achieve this recognition. In a letter to Dr. Blumencranz, CoC Committee on Cancer Liaison chairman Jon Greif, D.O., F.A.C.S., noted that Dr. Blumencranz was selected for the award for his “outstanding leadership and guidance as a physician champion in (the Morton Plant Mease) cancer program.”
Established in 1963, the Cancer Liaison Program of the Commission on Cancer was developed as a grassroots network of physician volunteers who manage clinically related cancer activities in local institutions and surrounding communities. The Cancer Liaison Physician Outstanding Performance Award recognizes physicians who go beyond their
regular scope of duties to improve and provide direction to cancer care programs in the following areas:
- Developed and/or implemented an idea(s) that improved the quality of care delivered
- Directly contributed to the approval status of the cancer program
- Worked above and beyond normal cancer liaison physician expectations to strengthen the cancer program
- Demonstrated leadership and support for cancer control activities in the community and with the American Cancer Society
- Served as a role model for other staff and exhibited characteristics that truly made him/her a physician champion for the cancer program
Award winners are chosen by the Committee on Cancer Liaison following an extensive review of nominations from a variety of sources including cancer leadership at a state level, American Cancer Society staff, CoC surveyors and other local and regional cancer leaders and team members.
In addition to receiving the Cancer Liaison Physician Outstanding Performance Award, Dr. Blumencranz has been honored by the Association of PeriOperative Registered Nurses of the Gulf Coast of Florida (AORN). In 2005 he received the Distinguished Innovative Surgeons Award for his research in breast cancer and advancements in lymphatic mapping and sentinel lymph node biopsy. Lymphatic mapping and sentinel lymph node (SLN) biopsy are techniques used in the surgical treatment of patients with melanoma (skin cancer) and breast cancer. A patient’s lymph nodes are mapped and then tissue samples taken from the lymph nodes to determine if cancer has spread to that area of the body and what course of treatment may be needed.
About the Commission on Cancer
Established by the American College of Surgeons (ACoS) in 1922, the multidisciplinary CoC establishes standards to ensure quality, multidisciplinary, and comprehensive cancer care delivery in health care settings; conducts surveys in health care settings to assess compliance with those standards; collects standardized data from CoC-approved health care settings to measure cancer care quality; uses data to monitor treatment patterns and outcomes and enhance cancer control and clinical surveillance activities, and develops effective educational interventions to improve cancer prevention, early detection, cancer care delivery, and outcomes in health care settings.
About Morton Plant Mease Health Care
Nationally recognized for health care excellence, Morton Plant Mease Health Care is dedicated to providing community owned health care services that set the standard for high-quality, compassionate care. Morton Plant Mease Health Care is comprised of the following hospitals – Morton Plant, Clearwater; Mease Dunedin, Dunedin; Mease Countryside, Safety Harbor and Morton Plant North Bay, New Port Richey.
Contact: Beth Hardy (727) 298-6199 Phone, (727) 402-8113 Pager or Amy Morrow (727) 461-8538 Phone, (727) 402-5975 Pager